Brief: Resmed Q4 Adjusted EPS USD 2.95 Vs. IBES Estimate USD 2.89
06/08/2026 21:06
BRIEF-Resmed Q4 Adjusted EPS USD 2.95 Vs. IBES Estimate USD 2.89 Aug 06 (Reuters) - Resmed Q4 revenue USD 1,500 million vs. IBES estimate USD 1,459 million.
- Q4 EPS USD 2.64
- Q4 adjusted gross margin 62.3%
Recent news on ResMed
See all newsCiti lifts ResMed's ASX-listed stock's target price after FX, valuation updates
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT